Ftse Mib
33.220,31
-0,29%
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
65.052,43
0,13%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Can Fite BioPharma Ltd (CANF) Can Fite BioPharma Ltd (CANF) Notizie

Can Fite BioPharma Ltd

CANF
2,73
-0,48 (-14,95%)
18 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/6/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/6/202413:00BWCan-Fite Received IRB Approval for the Treatment of..
07/6/202422:15EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
05/6/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202413:00BWCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase..
29/5/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202413:00BWIndependent Scientists Published a Review Article..
27/5/202413:00BWCan-Fite to Participate in Partnering Meetings at Bio..
23/5/202413:00BWJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
22/5/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202413:00BWCan-Fite: 75 Oncologists and Coordinators from Europe US and..
09/5/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202413:00BWCan-Fite: FDA Grants IND Clearance for Namodenoson to Treat..
06/5/202413:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202413:00BWCan-Fite Received Notice of Allowance from the European..
25/4/202413:00BWLong-term Complete Response to Can-Fite's Namodenoson in..
15/4/202413:00BWCan-Fite: Scientific Article Published by KOL Presents..
03/4/202413:00BWCan-Fite: Submits FDA with an IND Application to Conduct..
28/3/202412:00BWCan-Fite Reports 2023 Financial Results and Clinical Update
11/3/202412:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/3/202412:00BWNamodenoson Treatment for Pancreatic and Liver Cancer: Data..
28/2/202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202413:00BWCan-Fite Broadens its Strong Intellectual Property (IP) for..
14/2/202421:32EDGAR2Form SC 13G - Statement of acquisition of beneficial..
30/1/202413:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202413:00BWCan-Fite Expands the Out-Licensing Deal with Ewopharma to..
29/1/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202413:00BWCan-Fite: Top Scientific Journal Published Positive Data..
08/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202322:16EDGAR2Form F-3/A - Registration statement by foreign private..
20/12/202313:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202313:00BWThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular..
18/12/202313:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202313:00BWCan-Fite Received FDA Positive Response to Psoriasis..
12/12/202322:15EDGAR2Form F-3 - Registration statement by foreign private issuers
04/12/202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00BWCan-Fite’s Namodenoson for the Treatment of Pancreatic..
30/11/202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202313:00BWCan-Fite Reports Third Quarter 2023 Financial Results and..
22/11/202322:20EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/11/202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202319:53GLOBECan-Fite Announces Exercise of Warrants for Approximately..
21/11/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202313:00BWCan-Fite: Complete Response and 6.9 Years Overall Survival..
01/11/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202312:00BWCan-Fite Issues Business Update: All Clinical Programs and..
30/10/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202312:00BWCan Fite: Namodenoson Inhibits Pancreatic Carcinoma..
Apertura: 3,00 Min: 2,61 Max: 3,055
Chiusura: 3,21

La tua Cronologia

AMEX
CANF
Can Fite BioPharma
COIN
MOKUST
Mocktail
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network